Alto Neuroscience, Inc. ("Alto") (NYSE: ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced ...

Joel Beatty, an analyst from Robert W. Baird, has initiated a new Buy rating on Bright Minds Biosciences (DRUG).Don't Miss our Black Friday ...

Biased agonism at the 5-HT2C receptor is one of its key features and adds another layer of functional selectivity within a well-validated target. BMB-101 works exclusively via the Gq-protein ...

Enveric’s drug discovery engine has also uncovered molecules demonstrating enhanced preference for 5-HT2C receptors. “Included in our portfolio are several molecules, protected by issued ...

This data has been presented at Society for Neuroscience's annual meeting at the NIH Satellite Forum. The poster is available on www.brightmindsbio.com. BMB-201, a selective 5-HT2A/2C receptor agonist ...

as well as targeted serotonin 5-HT1A and 5-HT2C receptor agonists. “The granting of this patent in support of our CYB005 phenethylamines program reinforces our commitment to expanding the ...

Longboard Pharmaceuticals, now a wholly owned subsidiary of Lundbeck, presents scientific data in multiple poster presentations showcasing the potential of bexicaserin in Developmental and Epileptic ...